Affect Therapeutics
PrivateLast Round
Series B
Sep 23, 2025
Total Funding Raised
$49.3M
Company Overview
Affect Therapeutics operates in Healthcare & Life Sciences and is based in McLean, Virginia. Its latest recorded funding round was a Series B round in September 2025.
Affect Therapeutics is a digital health company that provides a smartphone-based virtual clinic for substance use and mental health disorders, utilizing contingency management, counseling, and medication-assisted treatment.
Sector
Healthcare & Life Sciences
Verticals
Mental Health, Telemedicine, Patient Engagement, Healthcare Analytics
Business Model
B2B2C
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Affect Therapeutics Comparables
Compare Affect Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| WEconnect Health Management | 82% | |
| Workit Health | 81% | |
| Monument | 80% |
For institutional investors. Book with your work email.
Affect Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 23, 2025 | ||||
| Series A | Jul 12, 2023 | ||||
| Grant | Sep 30, 2021 | ||||
| Seed | Aug 31, 2021 | ||||
| Seed | Apr 21, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Affect Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AlleyCorp | Seed, Series A |
| ARTIS Ventures | Series B, Series A |
| Allumia Ventures | Series B |
| Samsung Next TLV | Series A |
| LifeArc Ventures | Series B, Series A |
| Kapor Capital | Seed |
| Acumen | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 5, 2026
Monthly visitors increased 141% MoM.
- Sep 23, 2025
$26M round led by Allumia Ventures.
For institutional investors. Book with your work email.
Affect Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Affect Therapeutics's valuation, stock price, and market status.
Is Affect Therapeutics a public or private company?
Affect Therapeutics is a private company.
What is the current stock price of Affect Therapeutics?
Affect Therapeutics is a private company, so its shares have no public market price. Caplight tracks Affect Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Affect Therapeutics worth (valuation)?
Valuation information for Affect Therapeutics is not publicly available.
Can I buy Affect Therapeutics stock?
Affect Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Affect Therapeutics's last funding round?
Affect Therapeutics's most recent funding round was Series B on September 23, 2025.
Who are the main investors in Affect Therapeutics?
Key investors in Affect Therapeutics include ARTIS Ventures, Allumia Ventures.
Will Affect Therapeutics IPO soon?
No public IPO plans have been announced for Affect Therapeutics.
How can I track Affect Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Affect Therapeutics's shares on secondary markets.